Pentapeptidyl supramolecular assembly particle and application of pentapeptidyl supramolecular assembly particle as drug delivery carrier

Through the preparation of pentapeptide-based supramolecular assembled particles, the reaction of thymus pentapeptide with Schiff base of hyaluronic acid and glutaraldehyde has solved the anti-inflammatory function and targeting of drug delivery vehicles in the prior art, and achieved the Biocompatibility and procedural release simplifies the preparation process and improves drug delivery efficiency.

CN118903450AActive Publication Date: 2024-11-08SHANDONG UNIV
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
CN202410974445.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-19
Publication Date
2024-11-08
Estimated Expiration
2044-07-19

AI Technical Summary

Technical Problem

The prior art has failed to effectively develop biocompatible drug delivery vehicles with anti-inflammatory functions, structural control, stimulus responsiveness and specific targeting, especially in the use of short peptide-bound Schiff base supramolecular assembly technology.

Method used

Pentapeptide-based supramolecular assembly particles are self-assembled through the reaction of thymic pentapeptide with hyaluronic acid and glutaraldehyde in Schiff base to form spherical particles with anti-inflammatory activity and good biocompatible, which can be used in different pH environments. drugs of different dissolving properties are stable and loaded with drugs with different dissolution properties to achieve procedural release.

Benefits of technology

The specific drug loading capacity of water-soluble and fat-soluble drugs and the differential release rate of drugs with different solubility under the same conditions were achieved, anti-inflammatory activity and biocompatibility were demonstrated, preparation process was simplified and storage conditions were reduced.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118903450A_ABST
    Figure CN118903450A_ABST
Patent Text Reader

Abstract

The invention discloses pentapeptidyl supramolecular assembly particles and application of the pentapeptidyl supramolecular assembly particles as drug delivery carriers, and belongs to the field of biological assembly materials. TP5, HA and GA are prepared into carrier particles TGCP and TGCP / nHA with drug loading performance and potential anti-inflammatory performance, and the carrier particles have autofluorescence performance, can stably exist in neutral and alkaline environments, can be decomposed in an acid environment, can entrap small molecules with different dissolving properties and have certain programmed response performance under physiological and pathological pH. In-vitro experiment research finds that the carrier particle is good in biocompatibility, and in-vitro inflammatory cell induction experiments find that TGCP and TGCP / nHA have certain anti-inflammatory activity, expression of a cell inflammatory factor IL-6 can be inhibited, and the effect of inhibiting inflammation is achieved.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of biological assembly materials, and in particular relates to pentapeptide-based supramolecular assembly particles and applications thereof as drug delivery carriers. Background Art

[0002] The information disclosed in this background technology section is only intended to enhance the understanding of the overall background of the invention, and should not necessarily be regarded as an admission or any form of suggestion that the information constitutes the prior art already known to a person skilled in the art.

[0003] Inflammation is the body's defensive response to stimulation and is a common clinical pathological process. If the immune response is not controlled, it may lead to autoimmune or autoinflammatory diseases. In recent years, new functional biomaterials with the potential to reduce inflammation levels have been rapidly manufactured. However, it is still challenging to develop biocompatible drug delivery carriers with anti-inflammatory functions, controllable structures, stimulus responsiveness, and specific targeting.

[0004] Dynamic covalent chemistry is a powerful technology that can be combined with non-covalent interactions to guide molecular assembly and create supramolecular systems for self-healing materials, biomolecule modification and drug delivery, and is reversible under specific stimulus conditions. Among them, the Schiff base reaction involves the formation of an imine bond (-C=N-), which has attracted increasing attention due to its mild reaction conditions, fast reaction speed, and the autofluorescence and pH-responsive properties of the assembly system.

[0005] Glycosaminoglycan-based assembly materials show great potential in promoting wound healing due to their moisturizing and anti-inflammatory effects. Glycosaminoglycans with carboxyl and hydroxyl groups can form non-covalent interactions with other functional supramolecular assemblies. According to investigations, self-assembling peptide-based materials can be used as drug delivery carriers with high targeting and delivery efficiency. Short peptides have strong assembly capabilities and programmability. In the past few decades, people have synthesized and used a variety of short peptides to construct supramolecular assemblies with different morphologies and specific biological functions. However, there are still no reports on the use of short peptides combined with Schiff base supramolecular assembly technology to prepare biocompatible drug delivery carriers with anti-inflammatory function, controllable structure, stimulus responsiveness and specific targeting. Summary of the invention

[0006] In order to solve the shortcomings of the prior art, the purpose of the present invention is to provide a pentapeptide-based supramolecular assembly particle and its use as a drug delivery carrier. The pentapeptide-based supramolecular assembly particle provided by the present invention has anti-inflammatory activity, good biocompatibility, and a specific drug loading capacity for both water-soluble and fat-soluble drugs, and drugs with different solubilities have different release rates under the same conditions.

[0007] In order to achieve the above object, the technical solution of the present invention is:

[0008] The first aspect of the present invention provides a pentapeptide-based supramolecular assembly particle, which includes a biological short peptide with immunological activity and a cross-linking agent;

[0009] The biological short peptide and the cross-linking agent undergo a Schiff base reaction in a reaction system and obtain pentapeptide-based supramolecular assembly particles through supramolecular self-assembly.

[0010] In some embodiments of the present invention, the biological short peptide includes thymopentin (TP5), and the cross-linking agent is a small molecule aldehyde.

[0011] In some embodiments of the present invention, the reaction system is water containing an organic solvent or water.

[0012] In some embodiments of the present invention, the pentapeptide-based supramolecular assembly particles are spherical.

[0013] In some embodiments of the present invention, the pentapeptide-based supramolecular assembly particles further include glycosaminoglycan compounds.

[0014] Preferably, the biological short peptide is thymopentin, the glycosaminoglycan compound is hyaluronic acid (HA), and the cross-linking agent is glutaraldehyde (GA); the molar ratio of thymopentin to hyaluronic acid is 1:0 to 1:8, and the molar ratio of thymopentin to glutaraldehyde is 1:1 to 1:3.

[0015] The second aspect of the present invention is a method for preparing the pentapeptide-based supramolecular assembly particles, comprising the following steps:

[0016] A cross-linking agent solution is added to a mixed solution containing biological short peptides and glycosaminoglycan compounds, and the mixture is allowed to stand to obtain pentapeptide-based supramolecular assembly particles;

[0017] The biological short peptide is thymopentin, the glycosaminoglycan compound is hyaluronic acid, and the cross-linking agent is glutaraldehyde; the molar ratio of thymopentin to hyaluronic acid is 1:0-1:8, and the molar ratio of thymopentin to glutaraldehyde is 1:1-1:3.

[0018] In some embodiments of the present invention, the molar ratio of thymopentin to hyaluronic acid is preferably 1:1, 1:4 or 1:8.

[0019] In some embodiments of the present invention, the molar ratio of thymopentin to glutaraldehyde is preferably 1:2.

[0020] In some embodiments of the present invention, the concentration of thymopentin in the mixed solution is 1 mg / mL-4 mg / mL, preferably 2 mg / mL;

[0021] The concentration of the glutaraldehyde solution is 8%-50% by mass, preferably 25%.

[0022] In some embodiments of the present invention, the molecular weight of the hyaluronic acid is 40-1000 kDa, preferably 780 kDa.

[0023] The pentapeptide-based supramolecular assembly particles provided by the present invention have biocompatibility, autofluorescence properties and pH responsiveness, and can be used as drug delivery carriers. Therefore, the third aspect of the present invention provides a use of the pentapeptide-based supramolecular assembly particles as a delivery carrier.

[0024] In some embodiments of the present invention, the application as a delivery vector includes but is not limited to any of the following:

[0025] (1) As a drug delivery vehicle;

[0026] (2) As a tool for studying the delivery performance of guest molecules; the guest molecules include drugs or model drugs; wherein the model drugs are drugs used to achieve disease modeling effects;

[0027] (3) As a model for exploring drug controlled release performance and programmed drug release;

[0028] (4) As a delivery vehicle for anti-inflammatory drugs.

[0029] A fourth aspect of the present invention provides a pharmaceutical preparation with intrinsic fluorescence properties, wherein the pharmaceutical preparation uses the pentapeptide-based supramolecular assembly particles to encapsulate the drug to be delivered;

[0030] The drugs include hydrophobic and hydrophilic drugs.

[0031] In some embodiments of the present invention, the method for preparing the pharmaceutical preparation comprises the following steps:

[0032] The drug to be delivered is added to a mixed solution containing thymopentin and hyaluronic acid, and then a glutaraldehyde solution is added, and the mixture is allowed to stand to obtain a drug preparation.

[0033] A fifth aspect of the present invention provides a use of the pentapeptide-based supramolecular assembly particles in the preparation of anti-inflammatory drugs.

[0034] In some embodiments of the present invention, the anti-inflammatory drug has the effect of reducing the concentration of inflammatory factors; preferably, the inflammatory factor is IL-6.

[0035] The beneficial effects of the present invention are:

[0036] The present invention discloses a thymopentapeptide-based carrier particle (TGCP) and a hyaluronic acid composite carrier particle (TGCP / HA) with biocompatibility and autofluorescence, wherein the carrier particle is a sustained-release carrier, which includes a biological short peptide thymopentapeptide (TP5) with immunological activity, a glycosaminoglycan compound hyaluronic acid (HA) with moisturizing, lubricating and potential anti-inflammatory properties, and a common cross-linking agent glutaraldehyde (GA) for compound cross-linking. The present invention makes TP5, HA and GA into carrier particles TGCP and TGCP / nHA with drug-carrying performance and potential anti-inflammatory performance, which have autofluorescence performance, and can stably exist in neutral and alkaline environments, can decompose in acidic environments, and can encapsulate small molecules of different solubility properties at the same time, and have certain programmatic response performance under physiological and pathological pH. The present invention explores and finds that the carrier particle has good biocompatibility through in vitro experiments, and for in vitro induced inflammatory cell experiments, it is found that TGCP and TGCP / nHA both have certain anti-inflammatory activity, can inhibit the expression of cellular inflammatory factor IL-6, and play an inhibitory effect on inflammation.

[0037] Compared with the complex preparation process, strict storage and use conditions of previous drug delivery carriers, the pentapeptide-based supramolecular assembly particles provided by the present invention have a simple preparation process, relatively simple structural components, good biocompatibility, and are easy to store. BRIEF DESCRIPTION OF THE DRAWINGS

[0038] The accompanying drawings in the specification, which constitute a part of the present invention, are used to provide a further understanding of the present invention. The exemplary embodiments of the present invention and their descriptions are used to explain the present invention and do not constitute improper limitations on the present invention.

[0039] Figure 1 Characterization of the properties of TGCP prepared in Example 1 of the present invention; wherein A is a scanning electron microscope (SEM) image of TGCP carrier particles dispersed in a water system; B is a SEM image of TGCP particles after ultrasound; C is a TGCP particle size distribution histogram and fitting curve drawn based on the statistical data measured by SEM; D is the TGCP particle size distribution measured by DLS;

[0040] Figure 2 The SEM images of the carrier particles TGCP / nHA prepared in Example 1 of the present invention; wherein A is a SEM image of TGCP / 1HA prepared when the molar ratio of TP5 to HA is 1:1; B is a SEM image of TGCP / 4HA prepared when the molar ratio of TP5 to HA is 1:4; C is a SEM image of TGCP / 8HA prepared when the molar ratio of TP5 to HA is 1:8;

[0041] Figure 3The fluorescence spectra and laser confocal imaging diagrams of the carrier particles prepared in Examples 1 and 2 of the present invention; wherein A is a fluorescence test spectrum diagram of TGCP carrier particles dispersed in water, and images collected under blue, green and red channels at a fixed excitation wavelength; B is a fluorescence test spectrum diagram of TGCP / 1HA carrier particles dispersed in water, and images collected under blue, green and red channels at a fixed excitation wavelength; C is a fluorescence test spectrum diagram of TGCP / 4HA carrier particles dispersed in water, and images collected under blue, green and red channels at a fixed excitation wavelength; D is a fluorescence test spectrum diagram of TGCP / 8HA carrier particles dispersed in water, and images collected under blue, green and red channels at a fixed excitation wavelength; the scale line shown in the laser confocal imaging diagram is 25 μm;

[0042] Figure 4 The stability of TGCP prepared in Example 1 of the present invention under different pH conditions; wherein A is the SEM image of TGCP in solutions with pH values ​​of 2.48, 3.76, 5.15, 7.44, 9.81 and 11.70; B is the SEM and TEM images of TGCP incubated in a PBS buffer solution with a pH value of 5.0 for 1, 5 and 10 days respectively; C is the SEM and TEM images of TGCP incubated in a PBS buffer solution with a pH value of 7.4 for 1, 5 and 10 days respectively;

[0043] Figure 5 The SEM images and drug release curves of TGCP prepared in Example 1 of the present invention after encapsulating small molecule drugs; wherein A is the SEM image of TGCP@AHI after encapsulating small molecule AHI; B is the SEM image of TGCP@PCA after encapsulating small molecule PCA; C is the drug release curve of TGCP@AHI; D is the drug release curve of TGCP@PCA;

[0044] Figure 6To evaluate the biocompatibility of the pentapeptide-based carrier particles prepared in Examples 1 and 2 of the present invention, the in vitro cell viability of NIH-3T3 and RAW264.7 was determined by CCK-8 method under different culture conditions (n=3); wherein A is the viability of NIH-3T3 cells under different concentrations of TGCP; B is the viability of NIH-3T3 cells under different concentrations of TGCP / 4HA; cell viability; C is the viability of NIH-3T3 cells under different concentrations of TGCP / 8HA; cell viability; D is the viability of NIH-3T3 cells under different concentrations of TGCP / 8HA; cell viability; CP@PCA for the viability of RAW264.7 cells; E is the viability of RAW264.7 cells at different concentrations of TGCP / 4HA@PCA; F is the viability of RAW264.7 cells at different concentrations of TGCP / 8HA@PCA; G is the viability of RAW264.7 cells at different concentrations of TGCP@AHI; H is the viability of RAW264.7 cells at different concentrations of TGCP / 4HA@AHI; I is the viability of RAW264.7 cells at different concentrations of TGCP / 8HA@AHI;

[0045] Figure 7 IL-6 concentration after culturing TGCP particles prepared in Example 1 of the present invention with RAW264.7 cells for 24 hours (n=3);

[0046] Figure 8 Graphs for evaluating the anti-inflammatory properties of the pentapeptide-based carriers prepared in Examples 1 and 2 of the present invention; wherein, A is the IL-6 concentration of RAW264.7 cells after culturing with TGCP@AHI for 24 hours (n=3); B is the IL-6 concentration of RAW264.7 cells after culturing with TGCP / 4HA@AHI for 24 hours (n=3); C is the IL-6 concentration of RAW264.7 cells after culturing with TGCP / 8HA@AHI for 24 hours (n=3); D is the IL-6 concentration of RAW264.7 cells after culturing with TGCP@PCA for 24 hours (n=3); E is the IL-6 concentration of RAW264.7 cells after culturing with TGCP / 4HA@PCA for 24 hours (n=3); F is the IL-6 concentration of RAW264.7 cells after culturing with TGCP / 8HA@PCA for 24 hours (n=3). DETAILED DESCRIPTION

[0047] The present invention provides a pentapeptide-based supramolecular assembly particle and its application as a drug delivery carrier. Compared with the complex preparation process, strict storage and use conditions of previous drug delivery carriers, the pentapeptide-based supramolecular assembly particle of the present invention has a simple preparation process, relatively simple structural components, and good biocompatibility.

[0048] The first typical embodiment of the present invention provides a pentapeptide-based supramolecular assembly particle, which includes a biological short peptide with immunological activity and a cross-linking agent;

[0049] The biological short peptide and the cross-linking agent undergo a Schiff base reaction in a reaction system and obtain pentapeptide-based supramolecular assembly particles through supramolecular self-assembly.

[0050] In some examples of this embodiment, the biological short peptide includes thymopentin (TP5), and the cross-linking agent is a small molecule aldehyde. The TP5 (Arg-Lys-Asp-Val-Tyr, RKDVY) is a polypeptide hormone secreted by the thymus, composed of five amino acids, and is an immunomodulatory pentapeptide with good biocompatibility and biodegradability.

[0051] In some examples of this embodiment, the reaction system is water containing an organic solvent or water.

[0052] The organic solvent includes, but is not limited to, methanol, ethanol or dimethyl sulfoxide, etc. The addition of the organic solvent can regulate the particle assembly process.

[0053] Wherein, the reaction system is water, preferably ultrapure water.

[0054] In some examples of this embodiment, the pentapeptide-based supramolecular assembly particles are spherical.

[0055] In some examples of this embodiment, the pentapeptide-based supramolecular assembly particles also include glycosaminoglycan compounds.

[0056] Wherein, the biological short peptide is thymopentin, the glycosaminoglycan compound is hyaluronic acid (HA), and the cross-linking agent is glutaraldehyde (GA); the molar ratio of thymopentin to hyaluronic acid is 1:0 to 1:8, and the molar ratio of thymopentin to glutaraldehyde is 1:1 to 1:3.

[0057] The present invention provides two types of pentapeptide-based supramolecular assembly particles, one of which is a pentapeptide-based supramolecular assembly particle (TGCP) obtained by a short peptide TP5 with immunological activity and a common chemical crosslinking agent in a reaction system and undergoing a Schiff base reaction and supramolecular self-assembly, and the other is a pentapeptide-based supramolecular assembly particle (TGCP / HA) obtained by a short peptide TP5 with immunological activity, a glycosaminoglycan compound hyaluronic acid (HA) with moisturizing, lubricating and potential anti-inflammatory properties and a common chemical crosslinking agent in a reaction system and undergoing a Schiff base reaction and supramolecular self-assembly. Both pentapeptide-based supramolecular assembly particles are sustained-release drug delivery carrier particles.

[0058] The present invention prepares the above three into carrier particles TGCP and TGCP / HA with drug-carrying properties and potential anti-inflammatory properties, which have spontaneous fluorescence properties, can stably exist in neutral and alkaline environments, can decompose in acidic environments, and can encapsulate small molecules with different solubility properties, and have certain programmed response properties under physiological and pathological pH. The present invention has found through in vitro experimental exploration that the carrier particles have good biocompatibility, and for in vitro induced inflammatory cell experiments, it is found that TGCP and TGCP / HA both have certain anti-inflammatory activity, can inhibit the expression of cellular inflammatory factor IL-6, and play a role in inhibiting inflammation.

[0059] A second typical embodiment of the present invention provides a method for preparing the pentapeptide-based supramolecular assembly particles, comprising the following steps:

[0060] A cross-linking agent solution is added to a mixed solution containing biological short peptides and glycosaminoglycan compounds, and the mixture is allowed to stand to obtain pentapeptide-based supramolecular assembly particles;

[0061] The biological short peptide is thymopentin, the glycosaminoglycan compound is hyaluronic acid, and the cross-linking agent is glutaraldehyde; the molar ratio of thymopentin to hyaluronic acid is 1:0-1:8, and the molar ratio of thymopentin to glutaraldehyde is 1:1-1:3.

[0062] The present invention provides a method for preparing the pentapeptide-based supramolecular assembly particles, and by adding glycosaminoglycan compounds such as hyaluronic acid (HA) to adjust the size and dispersibility of TGCP, the TGCP / HA has excellent injectability and synergistic anti-inflammatory activity.

[0063] In some examples of this embodiment, the molar ratio of thymopentin to hyaluronic acid is preferably 1:1, 1:4 or 1:8.

[0064] In some examples of this embodiment, the molar ratio of thymopentin to glutaraldehyde is preferably 1:2.

[0065] In some examples of this embodiment, the concentration of thymopentin in the mixed solution is 1 mg / mL-4 mg / mL, preferably 2 mg / mL;

[0066] The concentration of the glutaraldehyde solution is 8%-50% by mass, preferably 25%.

[0067] In some examples of this embodiment, the molecular weight of the hyaluronic acid is 40-1000 kDa, preferably 780 kDa.

[0068] In some examples of this embodiment, the reaction environment is static, including static in a light-proof environment, constant temperature preparation at a fixed speed in a shaker, preparation with magnetic stirring, and the like, preferably constant temperature preparation at a fixed speed in a shaker.

[0069] In some examples of this embodiment, for the preparation of TGCP, a certain proportion of GA aqueous solution is added to the TP5 aqueous solution, mixed evenly, and allowed to stand to obtain a turbid suspension with a yellow precipitate. The precipitate is washed by centrifugation with ultrapure water and stored in Milli-Q water at room temperature to obtain TGCP.

[0070] In some examples of this embodiment, for the preparation of TGCP / HA, TP5 and HA are dissolved in a certain molar ratio, and a certain proportion of GA aqueous solution is added, mixed evenly, and allowed to stand at room temperature in the dark to obtain a turbid suspended colloid with a yellow precipitate (a yellow precipitate appears when the molar ratio of HA to TP5 is small). The suspended colloid is dialyzed at room temperature in a dialysis membrane with a fixed molecular weight cutoff, and then freeze-dried to obtain TGCP / HA.

[0071] Wherein, the fixed molecular weight cut-off of the dialysis membrane is 100-7000Da, preferably 3500Da.

[0072] The pentapeptide-based supramolecular assembly particles provided by the present invention have biocompatibility, autofluorescence properties and pH responsiveness, and can be used as drug delivery carriers. Therefore, a third typical embodiment of the present invention provides an application of the pentapeptide-based supramolecular assembly particles as a delivery carrier.

[0073] In some examples of this embodiment, the application as a delivery vector includes but is not limited to any of the following:

[0074] (1) As a drug delivery vehicle;

[0075] (2) As a tool for studying the delivery performance of guest molecules; the guest molecules include drugs or model drugs; wherein the model drugs are drugs used to achieve disease modeling effects;

[0076] (3) As a model for exploring drug controlled release performance and programmed drug release;

[0077] (4) As a delivery vehicle for anti-inflammatory drugs.

[0078] A fourth typical embodiment of the present invention provides a drug preparation with intrinsic fluorescence properties, wherein the drug preparation uses the pentapeptide-based supramolecular assembly particles to encapsulate the drug to be delivered;

[0079] The drugs include hydrophobic and hydrophilic drugs.

[0080] In some examples of this embodiment, the method for preparing the pharmaceutical preparation comprises the following steps:

[0081] The drug to be delivered is added to a mixed solution containing thymopentin and hyaluronic acid, and then a glutaraldehyde solution is added, and the mixture is allowed to stand to obtain a drug preparation.

[0082] In a fifth typical embodiment of the present invention, a use of the pentapeptide-based supramolecular assembly particles in the preparation of anti-inflammatory drugs is provided.

[0083] In some examples of this embodiment, the anti-inflammatory drug has the effect of reducing the concentration of inflammatory factors; preferably, the inflammatory factor is IL-6.

[0084] The present invention also provides a method for loading model dyes and drug small molecules on pentapeptide-based supramolecular assembly particles, selecting a variety of hydrophilic and hydrophobic model dye molecules, and exploring the loading performance of TGCP or TGCP / HA by coprecipitation.

[0085] The loading method comprises the following steps: preparing a mixed aqueous solution of TP5 and a model dye or a model drug small molecule, or preparing a mixed aqueous solution of TP5, HA and a model dye or a model drug small molecule; adding a GA solution, standing, and forming a colored precipitate. Using ultraviolet-visible absorption spectroscopy, high performance liquid chromatography, etc., combined with a standard curve, the molecular weight of the dye or drug encapsulated by TGCP or TGCP / HA is determined.

[0086] The model dye may be cationic, anionic, water-soluble, water-insoluble, etc., and is preferably a water-insoluble dye small molecule.

[0087] The model drug small molecule may be water-soluble or fat-soluble, preferably fat-soluble.

[0088] The dye molecular weight or drug molecular weight loading amount can be measured by ultraviolet-visible absorption spectroscopy, fluorescence spectroscopy, high performance liquid chromatography, etc., preferably ultraviolet-visible absorption spectroscopy and high performance liquid chromatography.

[0089] In order to enable those skilled in the art to more clearly understand the technical solution of the present invention, the technical solution of the present invention will be described in detail below in conjunction with specific embodiments.

[0090] Unless otherwise specified, the reagents used in the following examples are conventional commercially available products and can be purchased.

[0091] Example 1 Preparation of TGCP

[0092] For TGCP: 1 mg TP5 was dissolved in 500 μL H2O. A certain proportion of 25 wt% GA aqueous solution was added to the TP5 solution, and the TP5 / GA molar ratio was 1:1, 1:2, and 1:3, respectively. The mixture was vortexed for 15 seconds and placed at room temperature in the dark for one day. A turbid suspension with yellow precipitate appeared at the bottom of the centrifuge tube. The precipitate was centrifuged and washed three times with ultrapure water, and then placed in Milli-Q pure water at room temperature to obtain TGCP carrier particles.

[0093] When the TP5 / GA molar ratio was 1:2, the obtained TGCP carrier particles were characterized by scanning electron microscopy. Figure 1 As shown in A, the precipitate is a uniform spherical particle with a smooth surface. After ultrasonic treatment, it is observed that the interior is porous and the edges are relatively loose ( Figure 1 B). This indicates that TGCP can provide a considerable space for the loading of guest molecules. Statistical analysis shows that the average diameter of TGCP is about 979.9nm ( Figure 1 C). The size measured by DLS is about 1046nm ( Figure 1 D), in addition, the zeta potential of the TGCP carrier particles was measured to be -35.35±2.92 mV.

[0094] Example 2 Preparation of TGCP / HA

[0095] For TGCP / nHA: 1 mg TP5 was dissolved in 500 μL H2O and HA powder was added. The mass of HA was determined according to the molar ratio of TP5 to HA repeating units (1:0.1 to 1:8). A 25 wt% GA aqueous solution with a molar ratio of TP5 to GA of 1:2 was added and vortexed for 60 seconds. After being placed at room temperature in the dark for 1 day, a yellow precipitate will be produced when the HA content is low, and a yellow suspension will be produced when the HA content is high due to high solution viscosity. To remove residual GA, the sample was dialyzed at room temperature using a 3500 Da dialysis bag with a molecular weight cutoff of 3500 Da for 3 days, during which the water was changed every 6 hours. The purified sample was freeze-dried to obtain the solid product TGCP / nHA, which was then stored at -80°C until further use.

[0096] Among them, TGCP / nHA with TP5 / HA molar ratios of 1:1, 1:4, and 1:8 were characterized by scanning electron microscopy, such as Figure 2 As shown in Figure 2, uniform spherical particles were obtained. Figure 2It can be seen that with the increase of HA content, the particle size of TGCP / nHA carrier particles gradually increases. When the TP5 / HA molar ratio is 1:1, the particle size of the obtained TGCP / 1HA carrier particles is about 284nm, when the TP5 / HA molar ratio is 1:4, the particle size of the obtained TGCP / 4HA carrier particles is about 374nm, and when the TP5 / HA molar ratio is 1:8, the particle size of the obtained TGCP / 8HA carrier particles is about 445nm. Therefore, the particle size of the pentapeptide-based supramolecular assembly particles can be adjusted by controlling the amount of HA.

[0097] Note: In order to distinguish the TGCP / HA carrier particles obtained with different TP5 / HA molar ratios, the carrier particles with a TP5 / HA molar ratio of 1:1 are named TGCP / 1HA, the carrier particles with a TP5 / HA molar ratio of 1:4 are named TGCP / 4HA, and the carrier particles with a TP5 / HA molar ratio of 1:8 are named TGCP / 8HA.

[0098] The following tests were performed using the TGCP carrier particles obtained in Example 1 with a TP5 / GA molar ratio of 1:2 and TGCP / 1HA, TGCP / 4HA, and TGCP / 8HA prepared in Example 2.

[0099] Example 3 Autofluorescence performance test of TGCP and TGCP / HA

[0100] The carrier particles TGCP and TGCP / nHA of this example have certain autofluorescence properties, which are tested by fluorescence spectrophotometer and confocal laser scanning microscope (CLSM) respectively to obtain the fluorescence spectrum and CLSM image of the sample.

[0101] The autofluorescence characteristics of TGCP and TGCP / HA were studied by fluorescence spectroscopy and CLSM. Figure 3 As shown. For TGCP( Figure 3 A), five broad emission peaks were observed at 448, 469, 520, 607, and 658 nm, indicating that the particles have blue, green, and red multi-wavelength fluorescence emission. This phenomenon is due to the n-π* transition of the Schiff base bond, indicating that the carrier particles have autofluorescence function. After non-covalent binding with HA, multi-wavelength fluorescence emission was also observed, but the emission wavelength was slightly different ( Figure 3 B. Figure 3 C. Figure 3 D.). The autofluorescence can be further confirmed in the CLSM images. When the excitation wavelength is 405 nm, the multi-wave autofluorescence characteristics of TGCP and TGCP / HA in the blue (430-480 nm), green (500-570 nm) and red (590-690 nm) bands are shown in Figure 2. Figure 3As shown. The addition of HA did not affect the autofluorescence characteristics of TGCP. In addition, after adding HA, the particle size decreased, which is consistent with the results of the scanning electron microscope image. Compared with carrier particles that require fluorescent labeling, interference from external chemical reagents is avoided, so the carrier particles of the present invention are more suitable as potential fluorescent carriers.

[0102] Example 4 Acid-base responsiveness of TGCP

[0103] This embodiment takes into account that the pH value of the inflammatory site is usually lower than that of normal tissue, so it will be more attractive to construct a carrier with pH responsiveness.

[0104] First, 100 μL of TGCP suspension at a concentration of 2 mg / mL was added to aqueous solutions with different pH values ​​(0.48, 2.48, 3.76, 5.15, 7.44, 9.81, 11.70, and 13.24, adjusted by 0.1 M NaOH and HCl) and cultured for more than 15 days. In addition, 100 μL of TGCP suspension at a concentration of 2 mg / mL was placed in a buffer solution with a pH value of 5.0 or 7.4 and cultured for more than 10 days. The samples were characterized at fixed times.

[0105] The prepared TGCP was added into acid-base solutions of different pH values ​​prepared by HCl and NaOH and mixed thoroughly. The morphological changes of TGCP when the pH value changed were observed by scanning electron microscopy ( Figure 4 A). When the pH value of the system reached 2.48 and 3.76, the structure of TGCP was significantly destroyed, forming an incomplete, broken spherical structure. When the pH value was 5.15, partial structural damage and particle adhesion were observed, and when the pH value increased from 7.44 to 11.70, no significant structural changes were observed. This shows that the TGCP prepared by the present invention is more stable in neutral and alkaline environments, but is easily decomposed in acidic systems and has a certain acid responsiveness.

[0106] Example 5 Stability of TGCP in buffer solution

[0107] In order to further study the stability of TGCP in neutral and acidic environments, this example used SEM and TEM to characterize the microstructural changes of TGCP dispersed in PBS buffer solutions with different pH values ​​after culturing for 1 day, 5 days and 10 days.

[0108] After TGCP was dispersed in PBS buffer solution with a pH value of 5.0 ( Figure 4B), some particles were damaged within one day, resulting in adhesion and accumulation. At the same time, TGCP with smooth surface and complete spherical shape could be found in the field of view of TEM. After five days of cultivation, almost all TGCP had formed a stacked state, and it was difficult to distinguish individual particles. The external structure of the particles found in the corresponding TEM field of view seemed to be damaged, and the outermost layer was loose. When the 10th day of cultivation, the shape of TGCP was increasingly difficult to recognize, and most TGCP was amorphous stacking or broken particles composed of assembly primitives. This characteristic of decomposition in an acidic environment shows that the TGCP carrier particles prepared by the present invention can be used as a drug container, which can release loaded drug molecules under pathological pH conditions.

[0109] There was no significant change in the morphology of TGCP after one day of culture in neutral PBS (pH 7.4) buffer solution ( Figure 4 C). TEM images also show a smooth and complete spherical morphology. Over time, the particle surface showed a slight dissociation, and the stacking of the TGCP surface became loose. After 10 days of culture in neutral PBS buffer, the structure gradually became loose because the unit stacking of the single TGCP was not tight enough. The results show that a small amount of H + The structure of TGCP can be destroyed. Therefore, the prepared carrier has the potential to release drugs under physiological pH conditions.

[0110] Example 6 Encapsulation properties of TGCP for small molecule dyes

[0111] Loading of model dye molecules: Thioflavin T (ThT), rhodamine B (RhB), toluidine blue (TB) and Nile red (NR) were selected as hydrophilic and hydrophobic dye molecular models, and the loading performance of TGCP was explored by coprecipitation. 500 μL of aliquots containing 1 mg TP5 were prepared, and the alcohol solution of NR (0.5 mg / mL, 60 μL), the alcohol solution of RhB (0.5 mg / mL, 60 μL), the aqueous solution of TB (0.85 mg / mL, 50 μL) or the aqueous solution of ThT (5 mg / mL, 50 μL) were added to the TP5 solution, and then 25 wt% GA solution was added to the mixture and vortexed for 30 seconds. After standing for 24 h, the supernatant was centrifuged at 8000 rpm for 30 min, the precipitate was separated and dissolved in DMSO (1 mL), and the amount of guest molecules ThT, TB, NR and RhB encapsulated in TGCP was determined using UV-visible absorption spectroscopy (Agilent Cary100) combined with a calibrated absorption curve.

[0112] The calculation formulas of drug loading (DL) and encapsulation efficiency (EE) are as follows:

[0113] DL%=(W tm -Wum / W tt )×100%

[0114] EE%=(W tm -W um / W tm )×100%

[0115] Among them, W tm is the total weight of the guest molecules; W um is the weight of the unbound guest molecule; W tt is the total weight of the bound guest molecule and TGCP. um The value was obtained by measuring the supernatant.

[0116] Encapsulating small molecules into carrier particles reflects the characteristics of the material and also expands its potential application areas. This embodiment uses small molecule dyes including amphoteric cationic dyes RhB, water-soluble cationic ThT and TB, and water-insoluble NR. Under the same conditions, the encapsulation efficiency (EE) and loading capacity (LC) of TGCP for RhB, ThT, TB and NR were evaluated according to the standard curve. The EE of RhB, ThT, TB and NR were 92.3%, 81.6%, 71.2% and 99.6%, respectively. The LC rates of RhB, ThT, TB and NR were 5.27%, 4.08%, 3.44% and 6.16%, respectively.

[0117] In addition, TGCP was used to encapsulate hydrophobic small drug molecules (curcumin and nifedipine). 500 μL of aliquots containing 1 mg TP5 were prepared, and an alcohol solution of curcumin (1 mg / mL, 50 μL) or an alcohol solution of nifedipine (4 mg / mL, 150 μL) was added to the TP5 solution, and then a 25 wt% GA solution was added to the mixture and vortexed for 30 seconds. After standing for 24 hours, the supernatant was centrifuged at 8000 rpm for 30 minutes, and the precipitate was separated and dissolved in DMSO (1 mL). The amount of hydrophobic small drug molecules (curcumin and nifedipine) encapsulated in TGCP was determined using UV-visible absorption spectroscopy (Agilent Cary 100) combined with a calibrated absorption curve.

[0118] TGCP still has ideal results for encapsulating hydrophobic small drug molecules (curcumin and nifedipine), with EE of 90.8% and 89.0%, respectively. The LC of curcumin and nifedipine are 5.75% and 4.45%, respectively. It can be seen that TGCP can effectively encapsulate hydrophilic and hydrophobic guest molecules.

[0119] Example 7 TGCP loading of model drug molecules

[0120] Traditional Chinese herbal medicines contain bioactive ingredients and have significant effects in reducing inflammation and promoting cartilage regeneration. Protocatechuic acid (PCA) and dehydrated icariin (AHI) as two hydrophilic and hydrophobic model drugs have been shown to have significant anti-inflammatory activity. This example prepares TGCP@drug encapsulating these two drugs. First, accurately weigh 1 mg TP5 and dissolve it in 500 μL H2O, add 5 μL AHI dimethyl sulfoxide solution (300 μM) or 50 μL PCA aqueous solution (3mM), mix for 60 seconds, add 25 wt% GA aqueous solution at a molar ratio of TP5 / GA of 1:2, vortex the mixture for 15 seconds, and place it at room temperature in the dark for 1 day. A turbid suspension and a light yellow precipitate appear at the bottom of the centrifuge tube. The samples are TGCP@AHI or TGCP@PCA, respectively.

[0121] To prepare TGCP / nHA@AHI and TGCP / nHA@PCA (n=4 or 8), TP5 and HA powders were dissolved in equal volumes of H2O at a molar ratio of 1:4 and 1:8, respectively. 5 μL of AHI alcohol solution (300 μM) or 50 μL of PCA aqueous solution (3 mM) was added and mixed for 120 seconds. 25 wt% GA aqueous solution was added at a molar ratio of TP5 / GA of 1:2. After standing at room temperature in the dark for 1 day, a turbid suspended colloid was obtained. The sample was freeze-dried to obtain a solid product, which was stored at -80°C until further use.

[0122] To determine the drug concentration and encapsulation, high performance liquid chromatography (HPLC, Agilent 1220 Infinity II) was used to analyze the loading efficiency. HPLC was performed on a ZORBAX SB-C18 column (4.6 × 250 mm) at a flow rate of 0.5 mL min -1 . For AHI, phase A was 0.1% phosphoric acid in water and phase B was methanol. The gradient of phase B was 80%-100% and the elution time was 20 min. The eluent was monitored at a wavelength of 270 nm using a UV detector. For PCA, the mobile phase was solvent A, which was 0.1% phosphoric acid in water, and solvent B was methanol. The gradient of phase B was 10%-50% and the elution time was 30 min. The elution process was monitored at a wavelength of 260 nm using a UV detector.

[0123] The TGCP prepared by the present invention has a certain carrying capacity for both hydrophilic and hydrophobic drug molecules. Figure 5 A. Figure 5B is the SEM image of TGCP@AHI and TGCP@PCA. The encapsulation amount and encapsulation efficiency of PCA and AHI were tested by HPLC. The EE and LC of PCA were 39.7% and 9.2%, respectively. The EE and LC of AHI were 61.9% and 3.4%, respectively. The encapsulation efficiency of TGCP for the water-insoluble small molecule AHI was higher than that of the water-soluble PCA.

[0124] Example 8 Drug release of TGCP under different pH conditions

[0125] The pH-responsive release of TGCP (i.e., TGCP@AHI and TGCP@PCA) after encapsulation of drug molecules (PCA, AHI) prepared in Example 7 was studied in PBS buffer solutions with pH values ​​of 7.4 and 5.0. After the prepared sample was centrifuged (8000rpm / min, 15min), the drug molecules not encapsulated by TGCP remained in the supernatant. 0.5mL of the supernatant was taken out for HPLC detection (the detection method was the same as the HPLC detection method in Example 7), and then an equal volume of fresh PBS buffer solution was added. The drug molecules were continuously released for 30 days in a constant temperature shaker at a temperature of 37.0°C and a rotation speed of 100rpm. According to the standard curve, the release of the drug molecules was quantitatively analyzed by high performance liquid chromatography, and the detection method was the same as the HPLC detection method in Example 7.

[0126] Compared with neutral conditions, the release rate of lipid-soluble AHI in acidic environment was more significant, and the release equilibrium was reached in about 11 days in PBS with a pH value of 5.0 ( Figure 5 C). However, under physiological pH conditions, the release continued to increase for about 22 days. The hydrophilic small molecule PCA showed a faster release rate in both acidic and neutral environments ( Figure 5 D). The reason for the slow release of hydrophobic drugs from TGCP may be the presence of hydrophobic spaces inside the particles. These drugs are adsorbed both inside the particles and on the outer surface of the particles. Therefore, the drugs are released slowly after the carrier particles are loosened. In contrast, TGCP has a weaker loading capacity for hydrophilic drugs than hydrophobic drugs, so the release rate is relatively fast.

[0127] Example 9 In vitro biocompatibility of TGCP

[0128] In vitro cytotoxicity experiments are often used to evaluate the biocompatibility of biomaterials because the experimental cycle is short, the sensitivity is high, and a large number of samples can be screened. Mouse embryonic fibroblasts (NIH-3T3) and mouse mononuclear macrophages (RAW264.7) were cultured in complete culture medium and passaged every 1.5 days at a fixed passage ratio. NIH-3T3 and RAW264.7 cells were seeded in 96-well plates. Compounds AHI, PCA, TGCP, TGCP / 4HA, TGCP / 8HA, TGCP@PCA prepared in Example 7, TGCP / 4HA@PCA, TGCP / 8HA@PCA, TGCP@AHI, TGCP / 4HA@AHI and TGCP / 8HA@AHI were diluted with medium solution to a suitable concentration gradient. A fixed amount of drug-containing culture medium was added to each well. The cells were incubated at 37.0°C for 24 hours and 48 hours. After incubation, CCK-8 solution was added, and the 96-well plate was incubated in a cell culture incubator in the dark for a certain period of time for color development. The absorbance at a fixed wavelength was read using an ELISA reader, and the data were processed using GraphPad Pism software. Each experiment was repeated at least 3 times.

[0129] For the in vitro cytotoxicity test of TGCP, the results are as follows Figure 6 As shown in A, even at a co-culture concentration of about 5 mg mL -1 There was no obvious cytotoxicity under the condition of TGCP / 4HA and TGCP / 8HA. These results indicate that TGCP has high biocompatibility and is suitable for biomedical applications. Under the same experimental conditions, the effects of TGCP / 4HA and TGCP / 8HA on the viability of NIH-3T3 cells were investigated at concentrations up to 5 mg mL -1 No obvious cytotoxicity was observed. Figure 6 BC). The results showed that the prepared particles had good biocompatibility with normal cells.

[0130] In order to explore the anti-inflammatory effect of drug carrier particles, RAW264.7 cells were used in this experiment. In order to prevent the survival rate of drug-loaded particles on macrophages RAW264.7 from affecting the anti-inflammatory results, this example tested the cell survival rate of drug-loaded particles after encapsulating drugs. Figure 6 D was used as an example, and a blank control group and a free drug control group were set up. The concentration of PCA was 0.3 mM, and the concentration of AHI was 3 μM. After culturing cells with a medium containing a certain amount of TGCP@PCA drug-loaded particles for 24 and 48 hours, the cell viability was evaluated by CCK-8 method. -1When TGCP@PCA was added, the survival rate of RAW264.7 cells exceeded 90%, indicating no obvious cytotoxicity. TGCP@PCA, TGCP / 4HA@PCA, TGCP / 8HA@PCA, TGCP@AHI, TGCP / 4HA@AHI, and TGCP / 8HA@AHI were also tested under the same experimental conditions. Figure 6 D. Figure 6 E. Figure 6 F. Figure 6 G. Figure 6 H. Figure 6 As shown in Figure 1, the prepared particles had no obvious toxic effects on RAW264.7 cells. This indicates that the particles have good biocompatibility and confirms that the drug-loaded particles do not affect the viability of cells.

[0131] Example 10 In vitro anti-inflammatory activity of TGCP

[0132] The in vitro anti-inflammatory activity of TGCP was tested by enzyme-linked immunosorbent assay (ELISA). RAW264.7 cells were seeded in 24-well plates and cultured overnight to allow the cells to adhere. The cells were then treated with lipopolysaccharide (LPS) to activate macrophage polarization. According to the grouping, DMEM culture medium containing different formulas was added after incubation for a period of time (untreated control group, lipopolysaccharide-induced positive control group, AHI, TGCP / nHA@AHI, TGCP / nHA@AHI). In order to measure the extracellular levels of proinflammatory factors, the supernatant was collected and the level of IL-6 was measured using an appropriate ELISA kit according to the protocol provided by the reagent company. Normal macrophages and activated macrophages without lipopolysaccharide treatment were used as the NT group and the control group, respectively.

[0133] The experiment used LPS-induced macrophages to detect the content of inflammatory factors in the cell supernatant. The NT group was macrophages that were not induced by LPS, and the control group was macrophages that were induced by LPS (5 μg mL -1 TGCP@AHI(l) and TGCP@AHI(h) were respectively the positive control group after LPS induction at low concentration (25 μg mL -1 ) and high concentration (250 μg mL -1 ) group. Single TGCP showed certain anti-inflammatory ability at high concentrations ( Figure 7 ), which may be related to the properties of TP5. Since TP5 is a type of immunologically active short peptide used for immunodeficiency treatment in the early years, its half-life is extended after being made into TGCP in this embodiment. This may lead to the release of a certain amount of TP5 during the administration process as TGCP is degraded, and show a specific anti-inflammatory effect.

[0134] The experimental results showed that even at low concentrations, TGCP@AHI was significantly different from the control group ( Figure 8 A). At high concentration (250 μg mL -1 ), the difference was more obvious. This suggests that TGCP@AHI can inhibit the production of inflammatory factors or reduce their concentrations. PCA, which also has anti-inflammatory potential, also obtained similar results ( Figure 8 D). However, at the same concentration, TGCP@AHI was less effective than TGCP@PCA in inhibiting the inflammatory factor IL-6. This may be due to the hydrophilicity of free PCA, which can promote the release of TGCP carriers, thereby releasing more drugs within 24 hours. In addition, after loading the drugs into TGCP / 4HA and TGCP / 8HA, the inflammatory factors in the cell supernatant were measured. The results still showed a certain anti-inflammatory effect. When the concentration of TGCP / 4HA@drug was high, the anti-inflammatory effect was enhanced. The results of TGCP / 8HA@drug also showed a specific concentration dependence. The results show that TGCP, TGCP / 4HA and TGCP / 8HA can still maintain their original inhibitory effect on IL-6 factors after encapsulating traditional Chinese medicine small molecules. As a supplement, they can reduce the concentration of inflammatory factors and are a potential anti-inflammatory carrier with sustained release effect, which can be used to treat inflammation-related diseases.

[0135] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. For those skilled in the art, the present invention may have various modifications and variations. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included in the protection scope of the present invention.

Claims

1. A pentapeptide-based supramolecular assembly particle, It is characterized in that It includes short biological peptides with immune activity and cross-linking agents; The biological short peptide and the cross-linking agent undergo a Schiff base reaction in a reaction system and obtain pentapeptide-based supramolecular assembly particles through supramolecular self-assembly.

2. The pentapeptide-based supramolecular assembly particle according to claim 1, It is characterized in that The biological short peptide includes thymopentin, and the cross-linking agent is a small molecule aldehyde; Or, the reaction system is water or water containing an organic solvent; Alternatively, the pentapeptide-based supramolecular assembly particles are spherical.

3. The pentapeptide-based supramolecular assembly particle according to claim 1 or 2, It is characterized in that The pentapeptide-based supramolecular assembly particles also include glycosaminoglycan compounds; Preferably, the biological short peptide is thymopentin, the glycosaminoglycan compound is hyaluronic acid, and the cross-linking agent is glutaraldehyde; the molar ratio of thymopentin to hyaluronic acid is 1:0 to 1:8, and the molar ratio of thymopentin to glutaraldehyde is 1:1 to 1:

3.

4. A method for preparing the pentapeptide-based supramolecular assembly particles according to claim 3, It is characterized in that The steps include: A cross-linking agent solution is added to a mixed solution containing biological short peptides and glycosaminoglycan compounds, and the mixture is allowed to stand to obtain pentapeptide-based supramolecular assembly particles; The biological short peptide is thymopentin, the glycosaminoglycan compound is hyaluronic acid, and the cross-linking agent is glutaraldehyde; the molar ratio of thymopentin to hyaluronic acid is 1:0-1:8, and the molar ratio of thymopentin to glutaraldehyde is 1:1-1:

3.

5. The method for preparing the pentapeptide-based supramolecular assembly particles according to claim 4, It is characterized in that The concentration of thymopentin in the mixed solution is 1 mg / mL-4 mg / mL; The concentration of the glutaraldehyde solution is 8%-50%, by mass percent.

6. The method for preparing the pentapeptide-based supramolecular assembly particles according to claim 4, It is characterized in that The molecular weight of the hyaluronic acid is 40-1000 kDa.

7. Use of the pentapeptide-based supramolecular assembly particles according to any one of claims 1 to 3 as a delivery vector.

8. Use of the pentapeptide-based supramolecular assembly particles as claimed in claim 7 as a delivery carrier, It is characterized in that The application as a delivery vector includes any of the following: (1) As a drug delivery vehicle; (2) As a tool for studying the delivery performance of guest molecules; the guest molecules include drugs or model drugs; wherein the model drugs are drugs used to achieve disease modeling effects; (3) As a model for exploring drug controlled release performance and programmed drug release; (4) As a delivery vehicle for anti-inflammatory drugs.

9. A pharmaceutical preparation having intrinsic fluorescent properties, It is characterized in that The pharmaceutical preparation uses the pentapeptide-based supramolecular assembly particles described in any one of claims 1 to 3 to encapsulate the drug to be delivered; The drugs include hydrophobic and hydrophilic drugs; The preparation method of the pharmaceutical preparation comprises the following steps: The drug to be delivered is added to a mixed solution containing thymopentin and hyaluronic acid, and then a glutaraldehyde solution is added, and the mixture is allowed to stand to obtain a drug preparation.

10. Use of the pentapeptide-based supramolecular assembly particles according to any one of claims 1 to 3 in the preparation of anti-inflammatory drugs; Preferably, the anti-inflammatory drug has the effect of reducing the concentration of inflammatory factors; further preferably, the inflammatory factor is IL-6.

Citation Information

Patent Citations

  • Thymopentin sustained release microsphere and its preparation method and application

    CN107198765A

  • Schiff base supramolecular assembly nanoparticles and application thereof as delivery carrier

    CN115282120A

  • Thymus pentapeptide slow-release microshpere formulation for injection and its preparation method

    CN1876173A